Compare TMCI & BNR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | TMCI | BNR |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | China |
| Employees | N/A | N/A |
| Industry | Biotechnology: Electromedical & Electrotherapeutic Apparatus | Medical Specialities |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 120.4M | 94.4M |
| IPO Year | 2021 | 2019 |
| Metric | TMCI | BNR |
|---|---|---|
| Price | $4.14 | $9.40 |
| Analyst Decision | Hold | |
| Analyst Count | 6 | 0 |
| Target Price | ★ $4.77 | N/A |
| AVG Volume (30 Days) | ★ 493.9K | 15.1K |
| Earning Date | 05-08-2026 | 06-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $212,690,000.00 | N/A |
| Revenue This Year | N/A | $111.65 |
| Revenue Next Year | $8.18 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.59 | N/A |
| 52 Week Low | $1.17 | $5.31 |
| 52 Week High | $7.78 | $41.72 |
| Indicator | TMCI | BNR |
|---|---|---|
| Relative Strength Index (RSI) | 50.61 | 46.02 |
| Support Level | $3.84 | $8.34 |
| Resistance Level | $4.67 | $10.00 |
| Average True Range (ATR) | 0.30 | 0.78 |
| MACD | -0.08 | -0.01 |
| Stochastic Oscillator | 31.67 | 17.10 |
Treace Medical Concepts Inc is a commercial-stage orthopaedic medical device company. It is focused on advancing the standard of care for the surgical management of bunion deformities. The company's patented Lapiplasty 3D Bunion Correction procedure is designed to reproducibly correct all planes of the bunion deformity and address the root cause of the bunion, while allowing patients to return to their active lives quickly. The Company operates and manages its business as one segment, which is the business of designing, manufacturing, and marketing medical devices for physicians, surgeons, ambulatory surgery centers and hospitals.
Burning Rock Biotech Ltd is a cancer diagnostics company. The Group provides pharma research and development services, mainly cancer therapy selection tests services, companion diagnostics development services, and other service agreements with the combination of various customized tests services and analytical validation services, to pharmaceutical companies for developing new drugs for targeted therapies, immunotherapies on various types of cancers, and to hospitals for their studies on cancer diagnosis & treatment. It had three operating segments, including the Central laboratory business, the In-hospital business, & Pharma research & development services. It generates the majority of its revenue from the Central laboratory business. Its products are Pan-HEME, OncoScreen-WES, & others.